Selected Grants
Positron Emission Tomography using 64Cu-SAR-bisPSMA in participants with high-risk prostate cancer prior to radical prostatectomy: A prospective, single-arm, multi-center, blinded-review, Phase 3 diagnostic performance study
Clinical TrialPrincipal Investigator · Awarded by Clarity Pharmaceuticals Pty Ltd (Clarity Pharmaceuticals) · 2024 - 2027ECOG-ACRIN Operations Center - Clinical Trials
ResearchPrincipal Investigator · Awarded by ECOG-ACRIN Medical Research Foundation Inc. · 2019 - 2026Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions after Progression on First Line Hormonal Therapy
Clinical TrialPrincipal Investigator · Awarded by Zionexa S.A.S. · 2023 - 2025A Prospective, Phase 3, Multi-Center, Single-Arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA-7.3 (18F) PET Ligand in Men with Newly Diagnosed Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Blue Earth Diagnostics · 2020 - 2022ECOG-ACRIN Operations Center Grant
ResearchPrincipal Investigator · Awarded by American College of Radiology Imaging Network · 2018 - 2019Simultaneous Emission and Transmission Mammotomography
ResearchInvestigator · Awarded by National Institutes of Health · 2002 - 2014ACRIN Committee or Subcommittee Chair Agreement
ResearchPrincipal Investigator · Awarded by American College of Radiology Imaging Network · 2013 - 2013Cross-disciplinary Training in Medical Physics
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2007 - 2013Radiation-Induced Cardiopulmonary Injury in Humans
ResearchInvestigator · Awarded by National Institutes of Health · 1996 - 2008Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
ResearchCo Investigator · Awarded by National Institutes of Health · 2003 - 2006Predicting Human Tumor Response by 31p MRS
ResearchCo Investigator · Awarded by National Institutes of Health · 1995 - 2001External Relationships
- Lantheus / Progenics pharmaceuticals
- Novartis pharmaceuticals
- telix pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.